Future of Homeopathy

Robert Melo M.D.
Overview

Status of Practice and Remedies
FDA & HPUS New regulations for manufacturing homeopathic remedies and their impact on the future development of homeopathy.

Obstacles for the development of homeopathy.

Proposed solution based on the faults from the conventional medicine model
HOMEOPATHY

PRACTICE OF HOMEOPATHY

HOMEOPATHIC REMEDIES
PRACTICE
STATE
REMEDIES

STATE AND FEDERAL
Senator Dr. Royal Samuel Copeland

(1868-1938)
Code of Federal Regulations

- OTC pharmaceutical
+++ practice and sales = +++ regulations
+++Enforcement
Practice: two options

Self Regulation

Government regulation
Remedies: One option
Homeopathic Pharmacopoeia
Convention of The United States

www.hpus.com

- (MRC) Monograph Review Committee
- (PRC) Pharmacopoeia Review Committee
- (CoP) Council on Pharmacy
- (S&C) Standards and Control Committee
- (T&S) Toxicology and Safety Committee
HPCUS proposes

FDA enforces
HPCUS

• Expiration date
• Stability testing for raw, intermediates and finish dilutions.
• Label indication for single remedies
• Plant growing protocols
• Heavy metal testing
• New Proving Guidelines
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>FOREWORD</td>
<td>5</td>
</tr>
<tr>
<td>2</td>
<td>PERSONNEL QUALIFICATIONS &amp; TRAINING</td>
<td>7</td>
</tr>
<tr>
<td>2.1</td>
<td>Principal Investigator</td>
<td>7</td>
</tr>
<tr>
<td>2.2</td>
<td>Project Coordinator / Administrator</td>
<td>7</td>
</tr>
<tr>
<td>2.3</td>
<td>Proving Subject Supervisors</td>
<td>7</td>
</tr>
<tr>
<td>2.4</td>
<td>Ethics Training</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>INVESTIGATIONAL PROVING SUBSTANCE</td>
<td>9</td>
</tr>
<tr>
<td>3.1</td>
<td>Investigational Proving Substance Manufacturer Information</td>
<td>9</td>
</tr>
<tr>
<td>3.2</td>
<td>Identity of IPS</td>
<td>9</td>
</tr>
<tr>
<td>3.3</td>
<td>IPS Manufacturing Process</td>
<td>10</td>
</tr>
<tr>
<td>3.4</td>
<td>Toxicology</td>
<td>10</td>
</tr>
<tr>
<td>3.5</td>
<td>Prior Clinical Information</td>
<td>10</td>
</tr>
<tr>
<td>3.6</td>
<td>Prior Proving of the IPS</td>
<td>11</td>
</tr>
<tr>
<td>4</td>
<td>DESIGN / METHODS</td>
<td>12</td>
</tr>
<tr>
<td>4.1</td>
<td>Overall Study Design and Plan</td>
<td>12</td>
</tr>
<tr>
<td>4.2</td>
<td>Controls</td>
<td>12</td>
</tr>
<tr>
<td>4.3</td>
<td>Selection of Study Population</td>
<td>13</td>
</tr>
<tr>
<td>4.4</td>
<td>Inclusion / Exclusion Criteria</td>
<td>13</td>
</tr>
<tr>
<td>4.5</td>
<td>IPS Characteristics</td>
<td>14</td>
</tr>
<tr>
<td>4.6</td>
<td>Randomization</td>
<td>15</td>
</tr>
<tr>
<td>4.7</td>
<td>Dosing Frequency</td>
<td>15</td>
</tr>
<tr>
<td>4.8</td>
<td>Criteria for Non-Repetition of Dose</td>
<td>15</td>
</tr>
<tr>
<td>4.9</td>
<td>Blinding</td>
<td>15</td>
</tr>
<tr>
<td>4.10</td>
<td>Therapeutic Intervention during Proving</td>
<td>16</td>
</tr>
<tr>
<td>4.11</td>
<td>Number of Subjects / Sample Size</td>
<td>17</td>
</tr>
<tr>
<td>4.12</td>
<td>Supervisor and Subject Interaction</td>
<td>17</td>
</tr>
</tbody>
</table>
5 Data Collection and Record Keeping

1. Data Labeling
2. Data Management
3. Subject Diary
4. Supervisor / Principal Investigator Inputs

Safety Assurance

1. Adverse Events
2. Serious Adverse Events
3. Single Subject Un-blinding in Connection with Adverse Events
4. Individual Subject Discontinuation from Proving
5. Event Handling Flow Chart

Data Analysis

1. Proving Symptoms
2. Relative Characterizing Features
3. Characteristic Symptoms
4. Clinical Synopsis of the IPS
5. Use of Control Results

Legal / Ethics

1. Ethics or Institutional Review Board
2. Informed Consent
3. Subject Withdrawal Criteria
4. Insurance coverage
5. Financial Disclosure Certification
QUALITY CONTROL
Laboratory Requirements

• Total Organic Carbon (purified water)
• High Pressure Liquid Chromatography (identification raw materials)
• Thin Layer Chromatography (identification raw materials)
• Spectrometer (identification raw materials)
• ICP mass spectrometer (heavy metal testing)
• Environmental chambers (stability testing)
• Microbiological testing (raw materials, in process testing and finish product)
UPSIDE

DOWNSIDE
Big heavy load for the US weak homeopathic industry
If you can not beat homeopathy with science or common sense, use their theory against their business model: GRAFTING.

The end of the homeopathy.

Why on Earth would anybody buy more than one pack of homeopathic remedy?

Whenever it's about to run out.

Just dilute it again!
Competition
Teamwork
Practitioners, Education, Industry
FEEDBACK
How we can do it better this time

Let’s explore the main faults of 60 years

• Leadership
• Science focus
• Socioeconomic model
Leadership
Evidence Based Medicine

3 Essential components:
1. Scientific Evidence:
   23% of highly cited RCTs later are refuted. J.P. Loannidis,
   JAMA, 2005; 294(2):218-228
2. Clinical Evidence
3. Patient Values

Evidence based medicine is not restricted to randomized trials and meta-analysis

From Lee Cowden M.D.
Ben Goldacre- “Bad Pharma”

- Medicine is broken
- Medicine is based on evidence??
- Examine the evidence..... flawed
- Research literature.... mostly hidden
- Education.... therapeutic...biased
- Regulators.....approve drugs with data on side effects withheld from doctors and patients
- Physicians... victims of the system
- Patients... suffer the consequences
Collect the Data!

www.project-redcap.org
ALL data
Therapeutic Effectiveness

Quality of Life Questionnaires: EORTC QLQ-C30
Different schools of thought

- Classical, contemporary, clinical, complex, individualized polypharmacy, Banerji protocols, Fibonacci series, spagyric, Schuessler Cell salts, drainage, isotherapy, anthroposophical, homotoxicology, pleomorphism, among others.
Socioeconomic model

Figure 1.3: The Circular Flow of Economic Activity

- Business income
  - Goods Services
  - Business income
- Product Markets
- Goods Services
- Consumer spending
- Individuals
  - Land Capital Labor Entrepreneurs
- Factor Markets
- Payments for resources
- Income from resources
- Buy productive resources
True Healing System
Integrative Health Care
Summary proposed plan

- Homeopathic remedies as tools
- Decrease homeopathic piracy and competition
- Increase certification for education
- Join HPCUS
- TEAMWORK Practitioners, Education, Industry
- Practitioners = LEADERS
- Collect, share and analyze ALL data
- Implement QLQ for patient evaluation
- Integrate homeopathy into healthcare
- Change the model from a disease/drug/profit to a health/preventive model
Thank You

rm@ohmpharma.com